FIELD: medicine; pediatrics; infectology.
SUBSTANCE: invention can be used to assess the effectiveness of antiviral therapy in infectious mononucleosis in children. 1,5 months after the antiviral treatment in children with acute infectious mononucleosis, blood serum is analyzed for fractalkine by enzyme immunoassay. If the blood serum fractalkine level is less than 8.8 ng/ml, the antiviral therapy is considered to be effective, and if the fractalkine level is more than 8.9 ng/ml, the antiviral therapy is considered to be ineffective.
EFFECT: method provides the possibility of increasing the evaluation of the effectiveness of antiviral therapy in children with acute infectious mononucleosis and allows to improve the clinical course and outcome of the disease by determining the blood level of fractalkine 1,5 months after the antiviral treatment.
1 cl, 1 tbl, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD FOR DIAGNOSING THE SEVERITY OF EPSTEIN-BARR VIRUS-INDUCED ACUTE INFECTIOUS MONONUCLEOSIS IN CHILDREN | 2022 |
|
RU2797960C1 |
| METHOD FOR ASSESSING EFFECTIVENESS OF ANTIVIRAL THERAPY IN INFECTIOUS MONONUCLEOSIS IN CHILDREN | 2023 |
|
RU2821177C1 |
| METHOD OF ASSESSING THE SEVERITY OF ACUTE INFECTIOUS MONONUCLEOSIS CAUSED BY THE EPSTEIN-BARR VIRUS IN CHILDREN | 2022 |
|
RU2798079C1 |
| METHOD FOR DETERMINING THERAPEUTIC APPROACH IN CHILDREN WITH ACUTE INFECTIOUS MONONUCLEOSIS | 2023 |
|
RU2821347C1 |
| METHOD OF PREDICTING RELAPSE OF EPSTEIN-BARR VIRAL INFECTION IN CHILDREN | 2023 |
|
RU2820959C1 |
| METHOD FOR DIFFERENTIAL DIAGNOSIS OF ACUTE AND CHRONIC CLINICAL COURSE OF INFECTIOUS MONONUCLEOSIS IN CHILDREN | 2015 |
|
RU2602454C1 |
| METHOD FOR ASSESSMENT OF ACTIVITY OF INFECTION CAUSED BY HERPES TYPE 4, 5 AND 6 IN CHILDREN | 2016 |
|
RU2639593C1 |
| METHOD OF FORECASTING SERIOUSNESS OF INFECTIOUS MONONUCLEOSIS OF VARIOUS ETIOLOGY AT CHILDREN | 2008 |
|
RU2360255C1 |
| METHOD FOR DIFFERENTIAL DIAGNOSIS OF CNS ORGANIC LESIONS IN CHILDREN DURING THE ACUTE PERIOD | 2017 |
|
RU2648215C1 |
| METHOD FOR SEVERITY DETERMINATION FOR ACUTE INFECTIOUS MONONUCLEOSIS CAUSED BY EPSTEIN - BARR VIRUS IN CHILDREN | 2016 |
|
RU2625505C1 |
